LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens

LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens

We have previously shown that through the production of high LIGHT levels, immune cells contribute to both osteoclastogenesis and bone destruction in Multiple Myeloma (MM)-related bone disease. With the aim of further exploring the mechanisms underlying the development of MM-related bone disease, he...

Full description

Bibliographic Details
Main Authors: Giacomina Brunetti, Rita Rizzi, Giuseppina Storlino, Sara Bortolotti, Graziana Colaianni, Lorenzo Sanesi, Luciana Lippo, Maria Felicia Faienza, Anna Mestice, Paola Curci, Giorgina Specchia, Maria Grano, Silvia Colucci
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-10-01
Series:Frontiers in Immunology
Subjects:
multiple myeloma
bone disease
LIGHT/TNFSF14
RANKL
CD14+/CD16+ monocytes
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.02459/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.02459/full

Similar Items